Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Fineline Cube Sep 7, 2026
Company Drug PIC

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

Fineline Cube Sep 7, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Fineline Cube Sep 7, 2026
Company Medical Device

Oriomics’ Liver Cancer Screening Reagent Earns FDA Breakthrough Device Designation

Fineline Cube Mar 24, 2025

Hangzhou-based Oriomics, a cancer screening specialist backed by Hotgen Biotech Co., Ltd (SHA: 688068), has...

Company Deals Drug

Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development

Fineline Cube Mar 24, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...

Company Drug

CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC

Fineline Cube Mar 24, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...

Company Deals

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy

Fineline Cube Mar 24, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with...

Company

Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation

Fineline Cube Mar 24, 2025

US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...

Company Drug

Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial

Fineline Cube Mar 24, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...

Company Drug

AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study

Fineline Cube Mar 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...

Medical Device Policy / Regulatory

NMPA Updates Rules on Domestic Production of Imported Medical Devices

Fineline Cube Mar 24, 2025

The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...

Company Medical Device

Broncus Medical’s BroncQCT Approved by Zhejiang Administration for China Market Entry

Fineline Cube Mar 24, 2025

Broncus Medical Inc., a provider of precision intervention solutions for lung diseases with operations in...

Company Medical Device

Lifetech Scientific’s LAmbre Plus LAA Closure System Gains US Medical Insurance Coverage

Fineline Cube Mar 24, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced obtaining medical insurance coverage in the United...

Company

Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs

Fineline Cube Mar 24, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...

Company

Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D

Fineline Cube Mar 24, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...

Company Drug

FDA Issues Second CRL to Hengrui’s Camrelizumab Combo Due to Manufacturing Issues

Fineline Cube Mar 24, 2025

The US Food and Drug Administration (FDA) last week issued another complete response letter (CRL)...

Company Legal / IP

AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development

Fineline Cube Mar 24, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment

Fineline Cube Mar 24, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving approval from the...

Company Legal / IP

Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations

Fineline Cube Mar 24, 2025

China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has disclosed that its subsidiary, Shanghai SINE...

Company Drug

HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment

Fineline Cube Mar 24, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National...

Company Deals

Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing

Fineline Cube Mar 24, 2025

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with...

Company Deals

Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases

Fineline Cube Mar 24, 2025

China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a...

Company Legal / IP

Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct

Fineline Cube Mar 24, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the...

Posts pagination

1 … 242 243 244 … 717

Recent updates

  • HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
  • NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
  • Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
  • Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
  • Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.